CL2015002689A1 - Métodos para inhibir cataratas y presbicia. - Google Patents

Métodos para inhibir cataratas y presbicia.

Info

Publication number
CL2015002689A1
CL2015002689A1 CL2015002689A CL2015002689A CL2015002689A1 CL 2015002689 A1 CL2015002689 A1 CL 2015002689A1 CL 2015002689 A CL2015002689 A CL 2015002689A CL 2015002689 A CL2015002689 A CL 2015002689A CL 2015002689 A1 CL2015002689 A1 CL 2015002689A1
Authority
CL
Chile
Prior art keywords
presbyopia
cataracts
inhibit
methods
presbicia
Prior art date
Application number
CL2015002689A
Other languages
English (en)
Inventor
Muthukumar Murugappan
Mohr Benjamin
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of CL2015002689A1 publication Critical patent/CL2015002689A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Abstract

METODO PARA INHIBIR EL AVANCE DE CATARATAS, PRESBICIA O DEGENERACION RELACIONADA CON LA EDAD, QUE COMPRENDE UN AGENTE DE ENMASCARAMIENTO DE CARGA DE GAMA-CRISTALINAS; UNA COMPOSICION OFTALMICA; UN METODO PARA TRATAR ENFERMEDADES RELACIONADAS CON EL PLEGAMIENTO PROTEICO COMO ENFERMEDAD DE ALZHEIMER, PARKINSON O HUNTINGTON
CL2015002689A 2013-03-14 2015-09-14 Métodos para inhibir cataratas y presbicia. CL2015002689A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782860P 2013-03-14 2013-03-14
PCT/US2014/027852 WO2014152818A1 (en) 2013-03-14 2014-03-14 Methods of inhibiting cataracts and presbyopia

Publications (1)

Publication Number Publication Date
CL2015002689A1 true CL2015002689A1 (es) 2016-02-05

Family

ID=50686164

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002689A CL2015002689A1 (es) 2013-03-14 2015-09-14 Métodos para inhibir cataratas y presbicia.

Country Status (20)

Country Link
US (3) US9789091B2 (es)
EP (1) EP2968239B1 (es)
JP (1) JP6397477B2 (es)
KR (1) KR102198622B1 (es)
CN (1) CN105209033B (es)
AU (1) AU2014236582B2 (es)
BR (1) BR112015023348B1 (es)
CA (1) CA2904657C (es)
CL (1) CL2015002689A1 (es)
CR (1) CR20150537A (es)
EA (1) EA029070B1 (es)
ES (1) ES2727293T3 (es)
HK (1) HK1218390A1 (es)
IL (1) IL241306B (es)
MX (1) MX366115B (es)
PE (1) PE20151747A1 (es)
SA (1) SA515361106B1 (es)
SG (1) SG11201507209SA (es)
WO (1) WO2014152818A1 (es)
ZA (1) ZA201506987B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209033B (zh) 2013-03-14 2018-09-18 马萨诸塞大学 抑制白内障和老花眼的方法
JP2018526423A (ja) * 2015-09-08 2018-09-13 ビューポイント セラピューティクス， インコーポレイテッド 眼科疾患を処置するための化合物および製剤
ES2745291T3 (es) * 2015-11-13 2020-02-28 Univ Massachusetts Moléculas difuncionales que contienen PEG para su uso en la inhibición de cataratas y presbicia
JP2022534420A (ja) * 2019-05-31 2022-07-29 プレックス ファーマスーティカルズ，インク 眼のタンパク質凝集疾患を治療するための薬剤
US11607064B2 (en) * 2019-08-06 2023-03-21 Dart Industries Inc. Reusable drinking straw
KR102587830B1 (ko) * 2021-07-22 2023-10-10 사회복지법인 삼성생명공익재단 딥러닝을 이용한 백내장 진단방법 및 시스템
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351826A (en) 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4526789A (en) * 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4665089A (en) 1985-03-21 1987-05-12 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US4620979A (en) 1985-08-02 1986-11-04 Schachar Ronald A Ophthalmological irrigating solution containing ascorbate
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
CA1269327A (en) 1986-04-24 1990-05-22 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US5055291A (en) 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4808182A (en) 1986-11-26 1989-02-28 Nestle, S.A. Deswelled, hydrogel intraocular lenses
US5338545A (en) 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5091421A (en) 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
DE3906311A1 (de) 1989-02-28 1990-08-30 Adatomed Pharma & Med Behandlungsystem zur verhinderung von nachstarbildung nach einer kataraktoperation
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
ATE138914T1 (de) 1990-12-10 1996-06-15 Bio Physio Pharmaceutical Rese Indeno-d-pyrimidonverbindungen zur verwendung in der medizin
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
RU94046058A (ru) * 1992-05-20 1996-10-20 Сендзю Фармасьютикал Ко. Агент для лечения и профилактики катаракты, способ его получения, применение (+) - (2s, 3s)-3 (s)-3-метил-1-(3-метилбутилкарбомоил)бутилкарбамоил]-2-оксикарбоновой кислоты ее соли и ее этилового эфира для получения агента, способ лечения и профилактики катаракты, способ получения водного раствора
US5375611A (en) * 1993-01-26 1994-12-27 Pharmacia Ab Method for preventing secondary cataract
CN1045383C (zh) 1993-04-07 1999-10-06 王慧康 用于治疗老年性白内障的药物组合物
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
EP0735895B1 (en) 1993-11-19 2006-01-18 The University Of Sydney A method for preventing or controlling cataract
US5516534A (en) 1993-11-26 1996-05-14 Rensselaer Polytechnic Institute Composition and method for reducing structural defects
US5591773A (en) 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
WO1995031223A1 (fr) 1994-05-13 1995-11-23 Kuraray Co., Ltd. Gel polymere a usage medical
EP0733918B1 (en) 1995-03-24 2003-07-30 Ocular Research of Boston, Inc. Hydrogel lens pre-coated with lipid layer
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP3599848B2 (ja) 1995-09-11 2004-12-08 株式会社メニコン 含水性軟質眼用レンズ用材料、それからなる含水性軟質眼用レンズ用成形体、ならびにそれからなる含水性軟質眼用レンズおよびその製法
EP0781777A1 (en) 1995-12-28 1997-07-02 Menicon Co., Ltd. Silicon-containing compound and ocular lens material
US5807944A (en) * 1996-06-27 1998-09-15 Ciba Vision Corporation Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom
DE69714663T2 (de) 1996-06-28 2003-04-10 Ube Industries Verfahren zur Herstellung von Polybutadien
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
JPH10339857A (ja) 1997-06-05 1998-12-22 Menicon Co Ltd 薬剤徐放性コンタクトレンズの製法およびそれによってえられた薬剤徐放性コンタクトレンズ
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
EP1149909A1 (en) 2000-04-28 2001-10-31 Boehringer Mannheim Gmbh Methods for regulating protein conformation using molecular chaperones
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
CA2389917A1 (en) 1999-11-04 2001-05-10 Kazunori Kataoka A polymer micelle as monolayer or layer-laminated surface
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
JP2003534383A (ja) 2000-05-31 2003-11-18 セラス コーポレイション 免疫原性が減少した赤血球の病原体不活性化溶液の調製
WO2002048190A1 (en) 2000-12-15 2002-06-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine as stabilizing agent of proteins
US6958224B2 (en) 2001-03-28 2005-10-25 Council Of Scientific And Industrial Research Chimeric protein α BNAC crystallin with extraordinarily high chaperone-like activity and a method related to the use thereof
US20030020870A1 (en) 2001-06-27 2003-01-30 Zms, Llc Biomedical molding materials from semi-solid precursors
US20040254197A1 (en) 2001-09-28 2004-12-16 Santen Pharmaceutical Co., Ltd. Injections for eye tissues containing drug bonded to polyethlene glycol
US20030223957A1 (en) * 2002-04-10 2003-12-04 Schwartz Daniel M. Biodegradable PEG based polymer formulations in ocular applications
US6924154B2 (en) 2002-08-20 2005-08-02 Quest Diagnostics Investments Incorporated Hydrophilic chemilumescent acridinium labeling reagents
JP2004161731A (ja) 2002-09-25 2004-06-10 Nof Corp 生体関連物質用固定化剤
EP2177620B1 (en) 2003-03-05 2014-11-19 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
CN1621091A (zh) 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
EP1711510A4 (en) 2004-02-05 2008-11-26 Intradigm Corp THERAPY WITH RNAI AGENTS APPLIED IN THE TREATMENT OF OCULAR DISEASES RESULTING FROM NEOVASCULARIZATION
WO2005112977A2 (en) 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2005110375A1 (en) 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
WO2005117987A1 (en) 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
WO2006052821A2 (en) * 2004-11-04 2006-05-18 University Of Washington Compositions and methods for treatment of protein misfolding and protein aggregation diseases
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CN1660920A (zh) 2005-02-01 2005-08-31 华东理工大学 末端连接ω－氨基酸的聚乙二醇酸或活性酯及制法和应用
DE102005041570A1 (de) 2005-09-01 2007-03-22 Celares Gmbh Hoch verzweigte Reagenzien zur Modifaktion von Biopharmazeutika, deren Herstellung und Anwendung
US7832875B2 (en) 2005-09-29 2010-11-16 Virtek Vision International Inc. Modulated diode pumped microchip laser projector
US20080094573A1 (en) 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US20070275098A1 (en) 2006-05-19 2007-11-29 T.R.P. Company, Inc, A Nevada Corporation Formulation and methodology for the treatment for eye impairment symptoms
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP5685773B2 (ja) 2007-09-07 2015-03-18 ミート アンド ライブストック オーストラリア リミテッド 血管新生および創傷治癒活性がある薬剤
WO2009051223A1 (ja) 2007-10-19 2009-04-23 R-Tech Ueno, Ltd. 白内障処置のための医薬組成物
KR20100000203A (ko) 2008-06-24 2010-01-06 인하대학교 산학협력단 금나노입자를 이용한 표적지향형 항암약물전달체
AU2009265021A1 (en) 2008-06-30 2010-01-07 Johnson & Johnson Vision Care, Inc. Methods and ophtalmic devices used in the treatment of ocular allergies
CN102099397B (zh) 2008-07-14 2012-12-12 拜康有限公司 合成低聚物的基本单分散混合物的方法
WO2010065024A1 (en) 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
WO2010096558A1 (en) * 2009-02-18 2010-08-26 Eyeon Particle Sciences Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
US8758802B2 (en) 2009-12-14 2014-06-24 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
US20130084262A1 (en) 2010-04-19 2013-04-04 Andrea S. Gobin Repairing bruch's membrane with hydrogels
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN102172410B (zh) 2011-01-14 2013-08-07 华南理工大学 用于癌症诊断与治疗的靶向纳米粒传输系统的构建方法
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CA2831855C (en) 2011-03-31 2019-05-21 Dh Technologies Development Pte. Ltd. Composition, method, and kit for calibrating a mass spectrometer
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
CN103582640B (zh) 2011-06-03 2015-11-25 3M创新有限公司 肼基1h-咪唑并喹啉-4-胺以及由其制成的缀合物
CN202172410U (zh) 2011-08-23 2012-03-21 东莞市铭普实业有限公司 一种基于物联网的带按键的射频智能光模块
RU2627184C2 (ru) 2011-09-04 2017-08-03 Глитек, Инк. Гликозилированные полипептиды и лекарственные композиции, содержащие данные полипептиды
MY171920A (en) 2011-10-12 2019-11-07 Ascendis Pharma Ophthalmology Div A/S Prevention and treatment of ocular conditions
CN102579353B (zh) 2012-03-30 2013-12-04 吉林大学 叶酸靶向的抗癌药物peg修饰的脂质体及制备方法
AU2013328782C1 (en) 2012-10-11 2018-01-18 Ascendis Pharma Ophthalmology Division A/S VEGF neutralizing prodrugs for the treatment of ocular conditions
US20150291672A1 (en) 2012-11-01 2015-10-15 The Johns Hopkins University Contact Lens Surface Modification with Hyaluronic Acid (HA) Binding Peptide for HA Accumulation and Retention
CN105209033B (zh) 2013-03-14 2018-09-18 马萨诸塞大学 抑制白内障和老花眼的方法
WO2014171842A1 (en) 2013-04-19 2014-10-23 Living Cell Technologies New Zealand Limited Biocompatible encapsulation system
WO2015085173A1 (en) 2013-12-05 2015-06-11 Wu Nian Polymer-carbohydrate conjugates for drug delivery technology
ES2745291T3 (es) 2015-11-13 2020-02-28 Univ Massachusetts Moléculas difuncionales que contienen PEG para su uso en la inhibición de cataratas y presbicia

Also Published As

Publication number Publication date
IL241306B (en) 2019-11-28
BR112015023348B1 (pt) 2023-04-25
SG11201507209SA (en) 2015-10-29
HK1218390A1 (zh) 2017-02-17
US9789091B2 (en) 2017-10-17
ZA201506987B (en) 2016-12-21
CA2904657A1 (en) 2014-09-25
BR112015023348A2 (pt) 2017-07-18
CR20150537A (es) 2015-11-27
US20160000707A1 (en) 2016-01-07
EA201591677A1 (ru) 2016-01-29
EP2968239B1 (en) 2019-04-24
KR20150130361A (ko) 2015-11-23
JP6397477B2 (ja) 2018-09-26
AU2014236582A1 (en) 2015-11-05
EA029070B1 (ru) 2018-02-28
ES2727293T3 (es) 2019-10-15
CN105209033A (zh) 2015-12-30
NZ713007A (en) 2020-11-27
KR102198622B1 (ko) 2021-01-05
PE20151747A1 (es) 2015-12-18
US10413529B2 (en) 2019-09-17
US20170231905A1 (en) 2017-08-17
MX2015013034A (es) 2016-07-05
JP2016517428A (ja) 2016-06-16
AU2014236582B2 (en) 2018-03-29
WO2014152818A1 (en) 2014-09-25
IL241306A0 (en) 2015-11-30
MX366115B (es) 2019-06-27
EP2968239A1 (en) 2016-01-20
SA515361106B1 (ar) 2018-09-25
CN105209033B (zh) 2018-09-18
US20160074370A1 (en) 2016-03-17
US9675589B2 (en) 2017-06-13
CA2904657C (en) 2021-02-16

Similar Documents

Publication Publication Date Title
CL2015002689A1 (es) Métodos para inhibir cataratas y presbicia.
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
CO2018006461A2 (es) Moléculas de anticuerpo contra april y usos de las mismas
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
AR102657A1 (es) Composición para tratar telas
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
IL240786A0 (en) Preparations, formulations and methods for treating eye diseases
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
CL2015002535A1 (es) Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis
EP3096617A4 (en) Compositions and methods for treating ocular diseases
BR112016021282A8 (pt) processos para a preparação de compostos antifúngicos e os referidos compostos
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
ECSP17035415A (es) 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
BR112016019825A2 (pt) anticorpos do fator bb do complemento
CO2017005404A2 (es) Anticuerpos contra il-6
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas
BR112017005272A2 (pt) uso de cisteamina no tratamento de infecções causadas por leveduras/bolores
ZA201703467B (en) Methods of treating ocular conditions